Rachael Nokes - 25 Feb 2022 Form 4 Insider Report for scPharmaceuticals Inc. (SCPH)

Role
Chief Financial Officer and Treasurer
Signature
/s/ Rachael Nokes
Issuer symbol
SCPH
Transactions as of
25 Feb 2022
Net transactions value
+$37,484
Form type
4
Filing time
23 Jan 2023, 16:54:37 UTC
Previous filing
01 Feb 2022
Next filing
19 Dec 2022
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction SCPH Common Stock Tax liability $19,988 -1,981 -14% $10.09 11,869 25 Feb 2020 Direct F1
transaction SCPH Common Stock Tax liability $14,366 -1,976 -17% $7.27 9,893 25 Feb 2021 Direct F1
transaction SCPH Common Stock Award $71,838 +11,700 +118% $6.14 21,593 19 Jan 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction SCPH Stock Option (right to buy) Award $0 +17,550 $0.000000 17,550 19 Jan 2023 Common Stock 17,550 $6.14 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The shares reported as disposed were withheld by the Issuer to satisfy tax withholding obligations of the Reporting Person related to the vesting of restricted stock units.
F2 Consists of a restricted stock unit ("RSU") award made pursuant to the ScPharmaceuticals Inc. 2017 Stock Option and Incentive Plan. The RSUs vest as to 25% of the shares underlying the RSUs on each of the first four anniversaries of January 1, 2023, such that the RSUs will be fully vested on January 1, 2027.
F3 The option shares vest over a four-year period, at a rate of 25% on January 1, 2024, with the remaining option shares vesting in 36 equal monthly installments thereafter, such that the option shares will be fully vested on January 1, 2027.

Remarks:

Chief Financial Officer and Treasurer